Diabetes Metabolism Res
A 1/4 cup of kimchi , which is a fermented food that provides live, active cultures to help improve the composition of our gut microbiome
Extended Data Figure 10 Comparison of G protein trimer structures from activated GLP-1RG s Nb35 complex and T4L- 2 ARG s Nb35 complex with alignment on G s Ras-like domain alone, related to Fig
This simple analogy is powerful because it perfectly distills a complex scientific barrier into an everyday concept
Over time, pharmacological engineering enabled: Short-acting injectables (e.g., exenatide) Long-acting once-weekly injectables (liraglutide, semaglutide) Multi-target incretin therapies (tirzepatide) Oral peptide formulations and now oral small molecules The most recent breakthrough is the development of orally available GLP-1 receptor agonists, including: Orforglipron (Lilly) Elecoglipron (AstraZeneca) These compounds eliminate the need for injection and could dramatically expand accessibility and adherence in obesity and diabetes populations
Addressing these challenges will require not only continued research and policy advocacy, but also culturally sensitive communication strategies to promote understanding, acceptance, and equitable access to GLP-1based treatments